Suncadia registers Phase 2 trial testing HRS-2129 against gout flare pain
The oral small molecule enters a Phase 2 test in acute gouty arthritis alongside a field of five active China-based programs, none sharing its target.
Executive Summary
- Shandong Suncadia Medicine has registered a Phase 2 trial of HRS-2129, an oral small molecule, testing whether it reduces acute gout flare pain faster and more than comparator treatment over the first days of an attack.
- The study is quadruple-masked with three treatment arms, a design built to isolate a real analgesic effect from placebo response in a condition that often resolves on its own within days.
- HRS-2129 enters a gout-flare and gout landscape crowded with China-based Phase 2 and Phase 3 programs testing different mechanisms, none of which shares its target, so the trial's result will not directly validate or undercut any single rival mechanism.
- Suncadia brings a clean execution record across dozens of prior trials into a study that has not yet started enrolling, so operational risk at this stage is about timing discipline rather than sponsor inexperience.
The registration
Suncadia's newly registered study, NCT07706777, will test HRS-2129 in patients experiencing an acute gout flare, measured by change in Visual Analogue Scale pain score from baseline to 24 hours after the first dose. The trial has not yet started recruiting, carries a planned enrollment of 90 patients across two sites in China, and targets a primary completion date of October 1, 2026. Secondary measures track pain at eight time points from one hour to 72 hours post-dose, daily pain change through 15 days, adverse-event incidence through 14 days after the last dose, and time to complete resolution of pain in the target joint. NCT07706777Clinical Study of HRS-2129 for Acute Gouty ArthritisNCT07706777
The design
The study is randomized, quadruple-masked, and structured with three arms. Enrollment requires a target-joint VAS pain score of at least 50 mm at screening, and excludes patients with a history of severe allergies, uncontrolled hypertension, prolonged QTc, or arrhythmias requiring treatment. That eligibility bar concentrates the trial on patients experiencing pain severe enough to make a 24-hour reduction clinically discernible, the design choice that gives the primary endpoint its power. NCT07706777Clinical Study of HRS-2129 for Acute Gouty ArthritisNCT07706777
The competitive field
Eight trials are active across gout, hyperuricemia, gout flare, primary gout, and acute gouty arthritis, spanning targets including xanthine oxidase, URAT1, interleukin-1 beta, and GM-CSF, none of which matches HRS-2129's target, which is not characterized in available competitive data. The nearest programs specific to acute gouty arthritis are Laboratorios Silanes' Etoricoxib, a COX-2 inhibitor in Phase 3 targeting completion in December 2026, and TJ Biopharma's Plonmarlimab, a GM-CSF-targeting monoclonal antibody in Phase 2 recruiting toward a 2027 completion. Both differ from HRS-2129 in modality or target, so neither offers a direct efficacy comparison; the field's five other active China-based programs also work through mechanisms distinct from each other, indicating a fragmented rather than a converging approach to gout-flare treatment.
The sponsor
Suncadia has completed all 31 of its prior trials with no terminations recorded, and currently runs 83 trials across all statuses, including 32 recruiting and 7 not yet recruiting. That track record supports operational credibility for a sponsor moving a new asset into Phase 2, though it says nothing yet about whether HRS-2129 itself will show an effect.
The regulatory backdrop
Older generic agents including indomethacin, prednisone, methylprednisolone, and dexamethasone carry FDA-approved indications covering acute gouty arthritis in the United States. HRS-2129 has no FDA approval history on record and no regulatory designation events attached to this program, consistent with a molecule still in early clinical testing rather than one nearing a regulatory decision.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.